Immunorizon, previously named ExploreBio1, was founded in late 2017 and is developing conditionally activated Tumor-Restricted T-and NK-Cell Engagers for cancer therapy. The company extends its pipeline and differentiates by using tri-specific constructs with additional tumor-associated antigens and diverse engagers with both T-cells and NK-cells. The company's platform maintains healthy tumor penetration in the human body, en...
Immunorizon, previously named ExploreBio1, was founded in late 2017 and is developing conditionally activated Tumor-Restricted T-and NK-Cell Engagers for cancer therapy. The company extends its pipeline and differentiates by using tri-specific constructs with additional tumor-associated antigens and diverse engagers with both T-cells and NK-cells. The company's platform maintains healthy tumor penetration in the human body, enabling physicians to protect patients' bodies from the harmful effects of toxicity.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.